朱孝峰，男，教授，研究員，實(shí)驗(yàn)研究部副主任，博士，博士生導(dǎo)師，1970年9月出生。中山大學(xué)腫瘤防治中心華南腫瘤學(xué)國(guó)家重點(diǎn)實(shí)驗(yàn)室課題負(fù)責(zé)人之一。中山醫(yī)科大學(xué)(現(xiàn)中山大學(xué))腫瘤學(xué)博士研究生畢業(yè)。2000年在美國(guó)喬治城大學(xué)癌癥中心結(jié)構(gòu)生物學(xué)與抗癌藥物研究實(shí)驗(yàn)室學(xué)習(xí)。榮獲第六屆中國(guó)藥理學(xué)會(huì)SERVIER青年藥理學(xué)工作者獎(jiǎng)。 《癌癥》雜志常務(wù)編務(wù)、《防癌報(bào)》編委，《中國(guó)科學(xué)》、《科學(xué)通報(bào)》、《Acta Pharmacologica Sinica》、《Planta Med》等雜志特約審稿人。近幾年來(lái)先后承擔(dān)國(guó)家自然科學(xué)基金四項(xiàng)，國(guó)家高新技術(shù)發(fā)展計(jì)劃（863計(jì)劃）分題，廣東省自然科學(xué)基金，廣東省科技計(jì)劃項(xiàng)目，廣州市科技計(jì)劃項(xiàng)目等項(xiàng)目。發(fā)表論文40余篇，其中在國(guó)際SCI收錄雜志發(fā)表論文19篇，主編專著二部。申請(qǐng)專利五項(xiàng)，其中二項(xiàng)為國(guó)際專利，二項(xiàng)中國(guó)發(fā)明專利已獲授權(quán)。作為主要研究人員之一完成的阿諾寧脂肪乳注射液抗腫瘤作用研究已轉(zhuǎn)讓企業(yè)開發(fā)。主要從事研究領(lǐng)域包括：腫瘤信號(hào)轉(zhuǎn)導(dǎo)途徑及靶向腫瘤異常信號(hào)轉(zhuǎn)導(dǎo)途徑的藥物研究。 近年發(fā)表的主要論文與專著(*為通訊作者) 1) Deng R, Li W, Guan Z, Zhou JM, Wang Y, Mei YP, Li MT, Feng GK, Huang W, Liu ZC, Han Y, Zeng YX, Zhu XF*. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene, 2006 May 22; [Epub ahead of print] 2) Zhou JM, Zhu XF*, et al. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene, 2006, 25, 503-511 3) Zhu XF, et al. Blockade of VEGF receptor signal pathway and antitumor activity of ON-III, a component from Chinese herbal medicine. Mol Pharmacol, 2005, 67(5):1444-1450. 4) Zhu JJ, Li FB, Zhou JM, Liu ZC, Zhu XF*, et al. The Tumor Suppressor p33(ING1b) Enhances Taxol-induced Apoptosis by p53-Dependent Pathway in Human Osteosarcoma U2OS Cells. Cancer Biol Ther, 2005,4(1):39-47. 5) Mei YP, Zhu XF*, et al. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Letters, 2006, 232, 189-198 6) Zhu JJ, Li FB, Zhu XF*, et al. The p33(ING1b) tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sciences, 2006, 78(13):1469-77 7) Zhu XF*, et al. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G phase in breast cancer cells. Cancer Science, 2006, 97(1): 84-89 8) Zhu XF, et al. Ceramide induces cell cycle arrest and upregulates p27kip in na...

暫無(wú)